Anthracycline metabolites from Streptomyces violaceus A262. II. New anthracycline epelmycins produced by a blocked mutant strain SU2-730.
New anthracycline antibiotics, identified as epsilon-rhodomycinone glycosides, were isolated from the culture broth of a blocked mutant of beta-rhodomycin-producing Streptomyces violaceus A262. They were designated as epelmycins A, B, C, D and E, and assayed for their in vitro cytotoxicities against murine leukemic L1210 cell culture and the antimicrobial activities in comparison with known anthracycline antibiotics.
Johdo
O
O
Central Research Laboratories, Mercian Corporation, Fujisawa, Japan.
Watanabe
Y
Y
Ishikura
T
T
Yoshimoto
A
A
Naganawa
H
H
Sawa
T
T
Takeuchi
T
T
D000818:Animals; D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D002855:Chromatography, Thin Layer; D004353:Drug Evaluation, Preclinical; D005285:Fermentation; D007939:Leukemia L1210 / Q000188:drug therapy; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D008826:Microbial Sensitivity Tests; D009154:Mutation / Q000235:genetics; D013302:Streptomyces / Q000235:genetics / Q000378:metabolism*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; C071803:epelmycin D; C071802:epelmycin C; C071801:epelmycin B; C071800:epelmycin A; C071804:epelmycin E